Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20296458 | 0.86 | DGAT1 (0.41) | MAPTGAAKDM4EGLAALDH1A1 | |
| SCHEMBL25679184 | 0.83 | ALDH1A1 (0.44) | MAPTKDM4EKEAP1CYP3A4NOTUM | |
| SCHEMBL23496847 | 0.83 | KEAP1 (0.40) | MAPTKDM4EKEAP1NOTUMNFE2L2 | |
| SCHEMBL30078020 | 0.81 | CYP3A4 (0.44) | MAPTGAAKDM4ECYP3A4GLA | |
| SCHEMBL17030866 | 0.81 | KDM4E (0.40) | MAPTGAAKDM4EKEAP1CYP3A4 | |
| SCHEMBL16647240 | 0.81 | CYP3A4 (0.44) | MAPTGAAKDM4ECYP3A4GLA | |
| SCHEMBL29810948 | 0.81 | KDM4E (0.40) | MAPTGAAKDM4EKEAP1CYP3A4 | |
| SCHEMBL20571238 | 0.81 | KDM4E (0.33) | GAAKDM4ENOTUMALDH1A1KMT2A | |
| SCHEMBL20571235 | 0.81 | KDM4E (0.33) | GAAKDM4ENOTUMALDH1A1KMT2A | |
| SCHEMBL16636921 | 0.80 | GAA (0.49) | MAPTGAAKDM4EGLAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | LEIDOS BIOMEDICAL RESEARCH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250362134-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2025236100-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2025-11-20 | — | — | WO | disclosed |
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | NNSA | 2025-08-28 | — | — | US | disclosed |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| US-RE50490-E1 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| EP-3055290-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2016049568-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | MAPT 2525/4885GAA 1458/4885KDM4E 3850/4885 |
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | MAPT 343/4885GAA 889/4885KDM4E 3720/4885 |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | MAPT 4504/4885GAA 648/4885KDM4E 3997/4885 |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MAPT 4487/4885GAA 2758/4885KDM4E 3345/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | MAPT 4509/4885GAA 712/4885KDM4E 4221/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | MAPT 279/4885GAA 2064/4885KDM4E 3220/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | MAPT 4504/4885GAA 648/4885KDM4E 3997/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | MAPT 3054/4885GAA 1317/4885KDM4E 1247/4885 |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | KRAS, NRAS, HRAS | MAPT 270/4885GAA 3748/4885KDM4E 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.